Advertisement
MTD vs TMO
Which Stock Would AI Choose? Mettler-Toledo International (MTD) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- MTD and TMO both reported second-quarter 2026 earnings beats with raised full-year guidance, reflecting improving demand in life sciences and industrial end markets.
- MTD delivered adjusted EPS of $11.46 (beat by $0.68) and 4.5% revenue growth, supported by China-led sales and productivity gains, while maintaining high operating margins near 30%.
- TMO posted $11.99 billion in revenue (10% reported growth, 5% organic) and adjusted EPS of $6.03, with management raising 2026 organic growth outlook to approximately 4% amid strengthening pharma and biotech activity.
- TMO recently completed the $1.1 billion divestiture of its microbiology business, streamlining its portfolio and returning capital via $1 billion in share repurchases during the quarter.
- MTD stock has seen recent institutional accumulation, including a new Bank of America stake, while both names trade at premium valuations with price-to-earnings ratios above 29.
- Relative performance shows MTD with higher margins and smaller scale versus TMO’s broader diversification and recurring revenue base in a recovering life sciences sector.
Introduction
MTD and TMO operate in the life sciences tools and services sector, supplying precision instruments, laboratory equipment, and analytical solutions to pharmaceutical, biotech, and industrial customers. This comparison examines their recent financial results, stock behavior, and market positioning to assist investors and traders evaluating relative opportunities in healthcare instrumentation. The analysis draws on verifiable developments from the past several weeks, including earnings reports and corporate actions, to highlight contrasts in scale, growth drivers, and risk profiles without forward-looking speculation.
MTD Overview and Recent Performance
MTD (Mettler-Toledo International Inc.) provides weighing, analytical, and product inspection instruments, with approximately 55% of sales tied to life sciences and 40% to industrial applications. In the second quarter of 2026, the company reported adjusted earnings per share of $11.46, exceeding estimates by $0.68, alongside 4.5% year-over-year revenue growth driven by strength in China and emerging markets. Management raised full-year local-currency sales guidance to 4-5% and adjusted EPS outlook accordingly. Recent market activity has included share price gains following institutional purchases, such as Bank of America’s disclosure of a new position, though analyst ratings remain mixed with a consensus Hold and average price target near $1,446. The stock has traded near $1,392 amid broader sector sentiment tied to laboratory demand recovery.
TMO Overview and Recent Performance
TMO (Thermo Fisher Scientific Inc.) offers a diversified portfolio spanning life sciences solutions, analytical instruments, specialty diagnostics, and biopharma services, generating the majority of revenue from pharma and biotech customers. Second-quarter 2026 results showed revenue of $11.99 billion, up 10% reported and 5% organic, with adjusted earnings per share of $6.03 beating consensus. The company raised full-year revenue guidance to $47.4-48.1 billion (6-8% growth) and organic growth outlook to approximately 4%. Recent developments include the completion of a $1.1 billion sale of its microbiology business and $1 billion in share repurchases. Shares have traded around $651, supported by improving customer activity and new institutional positions, within a 52-week range reflecting post-pandemic normalization in laboratory spending.
Trending AI Robots
Tickeron operates a platform featuring hundreds of AI trading bots that execute strategies across thousands of tickers using varied approaches, timeframes, and performance metrics. Only those demonstrating strong suitability for prevailing market conditions appear in the curated Trending AI Robots section. Available bots span ranges of historical win rates, average returns, and drawdown statistics depending on their specific strategies, with many focused on trend-following, mean-reversion, or momentum tactics. Users can review detailed performance data, ticker sets, and risk parameters for each bot. Review the Trending AI Robots page for current selections aligned with evolving market dynamics.
Head-to-Head Comparison
MTD operates with a narrower focus on precision measurement and inspection tools, delivering higher operating margins near 30% and greater sensitivity to industrial and laboratory capital spending cycles. In contrast, TMO benefits from greater scale, recurring revenue streams from consumables and services, and broader exposure across diagnostics and bioprocessing, which supported its 5% organic growth in the latest quarter. Both companies have raised guidance amid recovering demand, yet MTD carries higher valuation multiples relative to its smaller market capitalization while TMO has executed portfolio optimization through divestitures. Risk factors include MTD’s concentration in fewer end markets versus TMO’s exposure to regulatory and funding cycles in pharmaceuticals. Recent sentiment has favored both on earnings momentum, with institutional flows noted for each.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent earnings beats, organic growth acceleration, and relative stability from recurring revenue, Tickeron’s AI models currently assign a modestly higher probabilistic preference to TMO for its scale advantages and successful portfolio adjustments. MTD shows competitive strength in margin expansion and targeted market recovery but operates with greater cyclical exposure. This assessment reflects current data patterns rather than definitive outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTD is a Buy and TMO is a Buy.
MTD | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 67 | |
SMR RATING 1..100 | 3 | 60 | |
PRICE GROWTH RATING 1..100 | 36 | 24 | |
P/E GROWTH RATING 1..100 | 32 | 16 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is significantly better than the same rating for MTD (99). This means that TMO’s stock grew significantly faster than MTD’s over the last 12 months.
TMO's Profit vs Risk Rating (67) in the Medical Specialties industry is somewhat better than the same rating for MTD (100). This means that TMO’s stock grew somewhat faster than MTD’s over the last 12 months.
MTD's SMR Rating (3) in the Medical Specialties industry is somewhat better than the same rating for TMO (60). This means that MTD’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's Price Growth Rating (24) in the Medical Specialties industry is in the same range as MTD (36). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
TMO's P/E Growth Rating (16) in the Medical Specialties industry is in the same range as MTD (32). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
| MTD | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | 2 days ago 65% |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 61% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 62% |
| Advances ODDS (%) | 3 days ago 62% | 3 days ago 63% |
| Declines ODDS (%) | 17 days ago 66% | 19 days ago 62% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 64% |
| Aroon ODDS (%) | 2 days ago 65% | 2 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MTD’s FA Score shows that 2 FA rating(s) are green while TMO’s FA Score has 3 green FA rating(s).
- MTD’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MTD’s TA Score shows that 6 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- MTD’s TA Score: 6 bullish, 5 bearish.
- TMO’s TA Score: 4 bullish, 4 bearish.
Price Growth
MTD (@Medical Specialties) experienced а +8.57% price change this week, while TMO (@Medical Specialties) price change was +3.62% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.46%. For the same industry, the average monthly price growth was +7.34%, and the average quarterly price growth was +60.89%.
Reported Earning Dates
MTD is expected to report earnings on Nov 05, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (+3.46% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | -0.49% | ||
| A - MTD | 69% Closely correlated | -0.03% | ||
| BRKR - MTD | 67% Closely correlated | +0.28% | ||
| TMO - MTD | 63% Loosely correlated | -0.50% | ||
| AZTA - MTD | 61% Loosely correlated | -0.53% | ||
| RVTY - MTD | 59% Loosely correlated | +0.29% | ||
More | ||||